CRL · Charles River Laboratories International
29 filings
CRL 10-K Annual Reports
Charles River Laboratories International - 29 annual reports
CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 8, 2016
- 8-K · Jan 19, 2016
- 8-K · Feb 10, 2016
- 10-K · Feb 12, 2016
- 8-K · Mar 10, 2016
- 8-K · Apr 5, 2016
- 8-K · May 4, 2016
- 10-Q · May 4, 2016
- 8-K · May 16, 2016
- 8-K/A · May 16, 2016
- 8-K/A · Jun 15, 2016
- 10-Q · Aug 3, 2016
- 8-K · Aug 3, 2016
- 8-K · Nov 2, 2016
- 10-Q · Nov 2, 2016
- 8-K · Nov 2, 2016
- 8-K · Jan 10, 2017
- 10-K · Feb 14, 2017
- 8-K · Feb 14, 2017
- 8-K · Apr 26, 2017
- 8-K · May 10, 2017
- 10-Q · May 10, 2017
- 8-K · May 11, 2017
- 8-K · Jul 6, 2017
- 10-Q · Aug 9, 2017
- 8-K · Aug 9, 2017
- 8-K · Nov 9, 2017
- 10-Q · Nov 9, 2017
- 8-K · Nov 24, 2017
- 8-K · Jan 9, 2018
- 8-K · Jan 16, 2018
- 8-K · Feb 13, 2018
- 10-K · Feb 13, 2018
- 8-K · Feb 13, 2018
- 8-K · Feb 13, 2018
- 8-K · Mar 26, 2018
- 8-K · Apr 3, 2018
- 8-K · May 10, 2018
- 10-Q · May 10, 2018
- 8-K · May 14, 2018
- 8-K · Jun 14, 2018
- 8-K/A · Jun 14, 2018
- 10-Q · Aug 8, 2018
- 8-K · Aug 8, 2018
- 8-K · Aug 8, 2018
- 8-K · Aug 31, 2018
- 8-K · Oct 3, 2018
- 10-Q · Nov 7, 2018
- 8-K · Nov 7, 2018
- 10-K · Feb 13, 2019
- 8-K · Feb 13, 2019
- 8-K · Feb 15, 2019
- 8-K · Apr 30, 2019
- 8-K · May 1, 2019
- 10-Q · May 7, 2019
- 8-K · May 7, 2019
- 8-K · May 22, 2019
- 8-K · Jul 31, 2019
- 10-Q · Jul 31, 2019
- 8-K · Aug 2, 2019
- 8-K · Oct 1, 2019
- 8-K · Oct 21, 2019
- 8-K · Oct 23, 2019
- 10-Q · Nov 6, 2019
- 8-K · Nov 6, 2019
- 8-K · Feb 11, 2020
- 10-K · Feb 11, 2020
- 8-K · Mar 4, 2020
- 10-Q · May 7, 2020
- 8-K · May 7, 2020
- 8-K · May 8, 2020
- 8-K · Aug 5, 2020
- 10-Q · Aug 5, 2020
- 8-K · Oct 19, 2020
- 8-K · Oct 29, 2020
- 10-Q · Oct 29, 2020
- 10-K · Feb 17, 2021
- 8-K · Feb 17, 2021
- 8-K · Feb 17, 2021
- 8-K · Mar 9, 2021
- 8-K · Mar 23, 2021
- 8-K · Mar 29, 2021
- 8-K · Apr 23, 2021
- 10-Q · May 4, 2021
- 8-K · May 4, 2021
- 8-K · May 10, 2021
- 8-K · May 18, 2021
- 10-Q · Aug 4, 2021
- 8-K · Aug 4, 2021
- 10-Q · Nov 3, 2021
- 8-K · Nov 3, 2021
- 8-K · Nov 9, 2021
- 8-K · Nov 12, 2021
- 8-K · Dec 15, 2021
- 8-K · Dec 27, 2021
- 8-K · Jan 11, 2022
- 10-K · Feb 16, 2022
- 8-K · Feb 16, 2022
- 8-K · Mar 28, 2022
- 10-Q · May 4, 2022
- 8-K · May 4, 2022
- 8-K · May 12, 2022
- 8-K · Jun 8, 2022
- 8-K · Aug 3, 2022
- 10-Q · Aug 3, 2022
- 10-Q · Nov 2, 2022
- 8-K · Nov 2, 2022
- 8-K · Nov 30, 2022
- 8-K · Dec 6, 2022
- 10-K · Feb 22, 2023
- 8-K · Feb 22, 2023
- 8-K · May 11, 2023
- 10-Q · May 11, 2023
- 8-K · May 15, 2023
- 10-Q · Aug 9, 2023
- 8-K · Aug 9, 2023
- 10-Q · Nov 8, 2023
- 8-K · Nov 8, 2023
- 8-K · Nov 15, 2023
- 8-K · Jan 16, 2024
- 8-K · Jan 24, 2024
- 10-K · Feb 14, 2024
- 8-K · Feb 14, 2024
- 10-Q · May 9, 2024
- 8-K · May 9, 2024
- 8-K · May 10, 2024
- 8-K · Aug 7, 2024
- 10-Q · Aug 7, 2024
- 8-K · Nov 6, 2024
- 10-Q · Nov 6, 2024
- 8-K · Dec 13, 2024
- 8-K · Jan 14, 2025
- 10-K · Feb 19, 2025
- 8-K · Feb 19, 2025
- 8-K · Feb 21, 2025
- 8-K · May 7, 2025
- 10-Q · May 7, 2025
- 8-K · May 7, 2025
- 8-K · May 23, 2025
- 10-Q · Aug 6, 2025
- 8-K · Aug 6, 2025
- 8-K · Sep 16, 2025
- 8-K/A · Sep 19, 2025
- 8-K · Nov 5, 2025
- 10-Q · Nov 5, 2025
- 8-K · Nov 17, 2025
- 8-K · Dec 3, 2025
- 8-K · Jan 9, 2026
- 8-K · Jan 13, 2026
- 10-K · Feb 18, 2026
- 8-K · Feb 18, 2026
- 8-K · Feb 18, 2026
- 8-K · Feb 25, 2026
- 10-Q · May 7, 2026
- 8-K · May 7, 2026
- 8-K · May 11, 2026
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026
- 8-K · Sep 24, 2026
- 10-Q · Nov 4, 2026
- 8-K · Nov 4, 2026
- 8-K · Nov 9, 2026
- 2025Feb 18, 2026
Charles River Laboratories International Annual Report, Year Ended Dec 27, 2025
Charles River Laboratories International, Inc. (CRL) reported fiscal 2025 total revenue of $4.02 billion, down 0.9% from $4.05 billion in fiscal 2024, as lower DSA volumes outweighed higher RMS revenue. The company swung to a net loss available to common shareholders of $144.3 million (basic and diluted loss per share of $2.91), compared with net income of $10.3 million in 2024. The decline was driven by $210.97 million of intangible asset impairments, a $165.0 million goodwill impairment in Biologics Solutions, and a $102.0 million intangible impairment within RMS's Cell Solutions group. Operating income fell to $25.2 million (0.6% margin) from $227.3 million, and the effective tax rate was (42.9)%. Segment results show DSA revenue of $2.40 billion (59.8% of total) with operating income of $424.6 million, RMS revenue of $846.1 million with operating income of $44.6 million, and Manufacturing revenue of $766.4 million with an operating loss of $184.3 million. Management described early signs of demand improvement, particularly from large biopharma clients in DSA, and expects approximately $300 million in cumulative annualized cost savings by the end of 2026. Operating cash flow was $737.6 million, and total debt and finance leases were $2.1 billion at year-end. The company also disclosed that it acquired certain assets of K.F. (Cambodia) Ltd. in January 2026 for $510.0 million, plans to acquire the remaining 79% of PathoQuest SAS for approximately $60 million, and expects to divest non-core assets representing about 7% of 2025 revenue. Leadership is changing: James C. Foster will step down as CEO and Chair effective May 5, 2026, and Birgit Girshick has been appointed as his successor. The company faces ongoing litigation, including a putative securities class action that was partially reinstated on appeal in August 2025, and two stayed derivative lawsuits. Management says it cannot estimate the potential exposure from these matters. The SEC closed its investigation in November 2025 without recommending enforcement, and the DOJ closed its related grand jury and civil investigations in August 2025.
- 2024Feb 19, 2025
Charles River Laboratories International Annual Report, Year Ended Dec 28, 2024
Charles River Laboratories International, Inc. reported fiscal 2024 total revenue of $4.05 billion, down from $4.13 billion in fiscal 2023, a decrease of $79.4 million, or 1.9%, driven mainly by lower volume in its DSA business amid more cautious biopharmaceutical client spending. Operating income fell to $227.3 million (5.6% operating margin) from $617.3 million (14.9%), reflecting a $215.0 million goodwill impairment in the Biologics Solutions reporting unit, restructuring charges of $107.0 million, and a $27 million inventory charge tied to the non-human primate investigations. Net income available to common shareholders dropped to $10.3 million, or $0.20 per diluted share, from $474.6 million, or $9.22 per diluted share, in 2023. Cash flow from operations was $734.6 million, and the company ended the year with $2.2 billion of debt and finance leases. Management expects restructuring actions to yield approximately $225 million of annualized cost savings and plans to close or consolidate about 15 additional sites over the next two years. The company repurchased $100.7 million of stock in 2024, had $899.3 million remaining under its authorization, and intends to repurchase about $350 million in 2025. The Credit Facility was reduced from $3.0 billion to $2.0 billion and extended to December 2029. The filing also highlights significant legal and regulatory exposure. U.S. DOJ and USFWS investigations into non-human primate shipments from Cambodia remain ongoing, with a parallel SEC inquiry, and a putative securities class action was dismissed in July 2024 and is on appeal. Two derivative lawsuits are stayed pending that appeal. The company also disclosed a January 2025 CDMO client complete response letter and an FDA Form 483 at a Company facility, and noted that the NIH's February 7, 2025 indirect-cost policy has been temporarily stayed.
- 2023Feb 14, 2024
Charles River Laboratories International Annual Report, Year Ended Dec 30, 2023
Charles River Laboratories International, Inc. (CRL) reported fiscal 2023 total revenue of $4.13 billion, up from $3.98 billion in 2022, an increase of $153.3 million or 3.9%, driven mainly by Safety Assessment volume and pricing and the Explora BioLabs acquisition, partially offset by the Avian divestiture. Operating income declined to $617.3 million (14.9% margin) from $651.0 million (16.4%), reflecting higher Manufacturing operating costs, restructuring and asset impairment charges, and the Avian divestiture. Net income attributable to common shareholders was $474.6 million, versus $486.2 million in 2022, while cash flow from operations rose to $683.9 million from $619.6 million. Segment revenue was RMS $792.3 million, DSA $2.62 billion (63.3% of total revenue), and Manufacturing $721.4 million. The filing highlights several risks. Non-human primate supply is constrained after the company voluntarily suspended shipments of Cambodia-sourced primates into the U.S. amid a DOJ and USFWS grand jury and civil investigation, an SEC inquiry, a putative securities class action and a derivative lawsuit. The company says it cannot predict the timing or outcome of these matters, including potential fines or liabilities. Total debt and finance leases were $2.6 billion, and the company completed the Noveprim acquisition, which lifted its stake to 90%. Discovery Services demand declined and DSA backlog fell to $2.45 billion from $3.15 billion. Restructuring charges were about $30 million, with expected annualized savings of $60 million to $70 million. The company had $129.1 million remaining under its $1.3 billion stock repurchase authorization and did not repurchase shares in the fourth quarter. It paid no cash dividends in 2023 and does not plan to in the coming year.
- 2022Feb 22, 2023
Charles River Laboratories International Annual Report, Year Ended Dec 31, 2022
Charles River Laboratories International, Inc. reported fiscal 2022 total revenue of $3.98 billion, up from $3.54 billion in 2021, an increase of $435.9 million, or 12.3%. Growth was led by the Discovery and Safety Assessment (DSA) segment, which generated $2.45 billion of revenue (up 16.1%) and operating income of $532.9 million (21.8% of revenue). Research Models and Services (RMS) revenue was $739.2 million and Manufacturing revenue was $789.6 million. Consolidated operating income was $651.0 million (16.4% of revenue, down from 16.7%), and net income attributable to common shareholders rose to $486.2 million, or $9.48 diluted EPS. The result was aided by a $123.4 million gain on the divestiture of the Avian Vaccine Services business, completed in December 2022, and by a 53rd week in fiscal 2022 that the filing says contributed to revenue in each segment. The filing's most significant new matter is an investigation by the U.S. Department of Justice and U.S. Fish and Wildlife Service into the company's conduct regarding several shipments of non-human primates from Cambodia. The company received a grand jury subpoena on February 17, 2023, and says it is cooperating and believes the concerns are without merit. It has voluntarily suspended future Cambodia-sourced non-human primate shipments, and the inventory related to recent shipments carries an approximate value of $20 million. The company cannot predict the timing, outcome or possible fines, penalties or liabilities. Cash flow from operations declined to $619.6 million from $760.8 million, mainly due to working capital changes, and total debt and finance leases were $2.7 billion at year-end, with $3.0 billion of revolving credit capacity and $1.2 billion drawn. The company also completed the acquisition of Explora BioLabs in April 2022 for $284.5 million and agreed to acquire SAMDI Tech in January 2023 for a preliminary purchase price of $60 million. Backlog stood at approximately $3.1 billion for DSA, $282 million for RMS and $116 million for Manufacturing at year-end 2022. The company did not repurchase shares under its program in the fourth quarter and had $129.1 million remaining authorization.
- 2021Feb 16, 2022
Charles River Laboratories International Annual Report, Year Ended Dec 25, 2021
Charles River Laboratories International, Inc. (CRL) reported fiscal 2021 total revenue of $3.54 billion, up from $2.92 billion in fiscal 2020, a 21.1% increase, with growth across all three reportable segments. Operating income rose to $589.9 million (16.7% of revenue) from $432.7 million (14.8%), and net income attributable to common shareholders was $391.0 million, up from $364.3 million. Management attributed the results to strong demand for discovery and safety assessment services, recovery in research models from the COVID-19 disruption of the prior year, and contributions from recent acquisitions, principally Cognate BioServices and Vigene Biosciences in the Manufacturing segment. The company expanded its cell and gene therapy CDMO footprint through the 2021 acquisitions of Cognate ($879.0 million preliminary purchase price), Vigene ($323.9 million), Retrogenix and Distributed Bio, and it sold RMS Japan and its Swedish CDMO site in October 2021. Cash provided by operating activities was $760.8 million, versus $546.6 million in 2020, while investing outflows were $1.44 billion, mainly for acquisitions. Total debt and finance leases stood at $2.7 billion at year-end, and the company issued $1.0 billion of 2029 and 2031 Senior Notes and extended its revolving credit facility to $3.0 billion maturing in April 2026. The filing also flags material risks, including client demand tied to biopharmaceutical R&D funding, government NIH funding, supply constraints for large research models, contamination risk, competition, data privacy and cybersecurity, and goodwill and intangible impairment, with goodwill and other intangibles totaling $3.8 billion. The company did not repurchase shares in 2021, had $129.1 million remaining under its repurchase authorization, and does not pay cash dividends.
- 2020Feb 17, 2021
Charles River Laboratories International Annual Report, Year Ended Dec 26, 2020
Charles River Laboratories International, Inc. (NYSE: CRL) reported fiscal 2020 total revenue of $2.92 billion, up from $2.62 billion in 2019, an increase of $302.7 million, or 11.5%. Growth was driven mainly by the Discovery and Safety Assessment (DSA) segment, whose revenue rose $218.4 million, or 13.5%, to $1.84 billion, and by Manufacturing Support, which rose 10.8% to $515.4 million. Research Models and Services (RMS) revenue rose 6.3% to $571.1 million, but its operating income fell 23.3% to $102.7 million as COVID-19 reduced demand for research models in the second quarter. Consolidated operating income rose 23.2% to $432.7 million, and net income attributable to common shareholders increased to $364.3 million from $252.0 million, helped by $100.9 million of net gains on venture capital and strategic equity investments. Cash flow from operations was $546.6 million, compared with $480.9 million in 2019. Total debt and finance leases were $2.0 billion at December 26, 2020, and the company had $129.1 million remaining under its stock repurchase program, with no repurchases in fiscal 2020. The filing states the company does not expect to pay cash dividends in the foreseeable future. Acquisitions in 2020 included HemaCare and Cellero, and the company signed an agreement on February 17, 2021 to acquire Cognate BioServices, Inc. for approximately $875 million in cash, expected to close by the end of the first quarter of 2021 and to be financed with cash and Credit Facility borrowings. Risk factors highlighted by the filing include the continuing COVID-19 pandemic, dependence on limited sources of large research models (with China supplying a significant portion of certain critical models), the financial risk of contracts that may be terminated or underpriced, cybersecurity (including a March 2019 unauthorized access incident), and LIBOR phase-out affecting the credit facility that matures in fiscal 2023.
- 2019Feb 11, 2020
Charles River Laboratories International Annual Report, Year Ended Dec 28, 2019
Charles River Laboratories International, Inc. reported fiscal 2019 total revenue of $2.62 billion, up from $2.27 billion in fiscal 2018, an increase the filing states as $355.1 million, or 15.7%. Growth was driven mainly by the Discovery and Safety Assessment (DSA) segment, which generated $1.62 billion of revenue, up 22.9%, helped by the Citoxlab and MPI Research acquisitions and by demand from biotechnology clients. Research Models and Services (RMS) revenue was $537.1 million, up 3.3%, and Manufacturing revenue was $465.1 million, up 8.3%. Operating income rose to $351.2 million from $331.4 million, though operating margin declined to 13.4% from 14.6%. Net income attributable to common shareholders increased to $252.0 million, or $5.07 diluted EPS, helped by a $20.6 million deferred tax asset recognized for net operating losses expected to be used in the future. The balance sheet grew with acquisitions. Total debt and finance leases were $1.91 billion at year end, with the company funding the Citoxlab acquisition ($527.7 million) and issuing $500.0 million of 4.25% Senior Notes due 2028 in October 2019. The revolving credit facility was increased to $2.05 billion in November 2019. Subsequent to year end, in January 2020, the company acquired HemaCare Corporation for approximately $380 million in cash, funded through cash on hand and borrowings under the revolver. Cash flow from operations was $480.9 million in 2019, compared with $441.1 million in 2018. The filing also discloses a March 2019 unauthorized access to certain information systems that copied client data, which the company states has been remediated, with a financial impact it describes as not material. The company reported $129.1 million remaining under its stock repurchase authorization and did not repurchase shares under the program in 2019. It stated it is not party to any legal proceedings that are material to its business.
- 2018Feb 13, 2019
Charles River Laboratories International Annual Report, Year Ended Dec 29, 2018
Charles River Laboratories International, Inc. reported total revenue of $2,266,096 thousand ($2.27 billion) for fiscal 2018, up from $1,857,601 thousand in 2017, a 22.0% increase that the filing attributes primarily to growth in the DSA and Manufacturing segments and the acquisitions of MPI Research, KWS BioTest and Brains On-Line. Operating income rose to $331,383 thousand from $288,282 thousand, and net income attributable to common shareholders increased to $226,373 thousand from $123,355 thousand. Diluted earnings per share from continuing operations were $4.59, compared with $2.54 in 2017, helped by a lower effective tax rate of 19.3% versus 57.7%, which reflected the net effects of U.S. Tax Reform. Net cash provided by operating activities was $441,140 thousand, up from $318,074 thousand. The company's debt rose to $1,654,988 thousand in total debt at year-end 2018, driven by the $2.3B Credit Facility and a $500.0 million 5.5% Senior Notes offering used largely to fund the $829.7 million cash purchase of MPI Research. Cash flows from investing activities totaled $955,003 thousand in outflows, including $824,868 thousand for business acquisitions and $140,054 thousand in capital expenditures. The company did not repurchase shares under its program during 2018, leaving $129.1 million authorized. Management describes demand for its safety assessment and biologics services as robust, while research model demand outside China declined. Subsequent to year-end, on February 13, 2019, Charles River signed a binding offer to acquire Citoxlab for EUR 448 million in cash (approximately $510 million), expected to close in the second quarter of 2019 and to be financed through its revolving credit facility and cash. The filing also notes a planned termination of the U.S. pension plan, with the company expecting to complete the process over the next two years.
- 2017Feb 13, 2018
Charles River Laboratories International Annual Report, Year Ended Dec 30, 2017
Charles River Laboratories International, Inc. describes itself as a full service, early-stage contract research organization (CRO) with three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). In fiscal 2017, total revenue was $1,857.6 million, up from $1,681.4 million in 2016, an increase of $176.2 million, or 10.5%, driven mainly by DSA (revenue of $980.0 million, up 17.1%) and Manufacturing ($384.0 million, up 9.5%), while RMS revenue was essentially flat at $493.6 million. Operating income rose to $287.5 million from $237.4 million, and income from continuing operations was $125.6 million, compared with $156.1 million in 2016, reflecting a $104.6 million increase in the income tax provision. The provision included a $78.5 million estimate for the impact of U.S. Tax Reform, and the effective tax rate rose to 57.7% from 30.0%. The company's balance sheet and cash flow position changed meaningfully during the year. Net cash provided by operating activities was $318.1 million, and total debt was $1.1 billion at year end. The company also divested its CDMO business for $75.0 million in February 2017, acquired Brains On-Line in August 2017, and recorded an $18.1 million restructuring charge in the fourth quarter related to the planned closure of its Maryland RMS production facility. Cash and cash equivalents were $163.8 million at December 30, 2017. Looking ahead, the filing discloses a definitive agreement signed February 12, 2018 to acquire MPI Research for an expected preliminary purchase price of approximately $800 million in cash, expected to close early in the second quarter of 2018 and to be reported in the DSA segment. The company has a commitment for up to $830 million under a bridge loan facility to finance the transaction, and the filing notes a termination fee of $48 million, increasing to $56 million under specified circumstances. The company also acquired KWS BioTest in January 2018 for $20.3 million in cash.
- 2016Feb 14, 2017
Charles River Laboratories International Annual Report, Year Ended Dec 31, 2016
Charles River Laboratories International, Inc. reported total revenue of $1,681,432 thousand ($1.68 billion) for fiscal 2016, up from $1,363,302 thousand in 2015, with revenue growth of 23.3% driven largely by the WIL Research acquisition. Operating income rose to $237,419 thousand from $206,449 thousand, and income from continuing operations was $156,086 thousand, or $3.22 per diluted share. The company describes itself as a full-service, early-stage contract research organization with three segments: Research Models and Services (29.4% of 2016 revenue), Discovery and Safety Assessment (49.8%), and Manufacturing Support (20.9%). The year was dominated by acquisitions. Charles River acquired WIL Research for $604.8 million in April 2016, along with Blue Stream and Agilux, and it reported total debt of $1,212.7 million at year end, up from $836.0 million a year earlier. Net cash provided by operating activities was $300,375 thousand. The company also disclosed a subsequent event: on February 10, 2017 it divested its CDMO business to Quotient Clinical Ltd. for $75.0 million in cash, and on February 6, 2017 it settled the IDEXX patent litigation. The filing notes that demand for safety assessment services improved in 2016, particularly from biotechnology clients, and that demand from large biopharmaceutical clients for early discovery services fluctuated. Management highlights risks including outsourcing trends, government and R&D budget fluctuations, contamination in animal populations, fixed-price contracts, international operations, and a 100-basis-point rise in interest rates that would increase annual pre-tax interest expense by approximately $12.1 million. The company paid no cash dividends and had $69.7 million remaining under its stock repurchase authorization at year end.
- 2015Feb 12, 2016
Charles River Laboratories International Annual Report, Year Ended Dec 26, 2015
Charles River Laboratories International, Inc. ("CRL") describes itself as a full service, early-stage contract research organization (CRO) that provides research models, discovery and safety assessment services, and manufacturing support products and services. In 2015, total revenue was $1.36 billion (total revenue $1,363,302 thousand), up from $1.30 billion in 2014, and income from continuing operations before income taxes was $195.4 million. The company has three reporting segments: Research Models and Services (RMS, 34.7% of 2015 revenue), Discovery and Safety Assessment (DSA, 44.9%), and Manufacturing Support (20.4%). Net income attributable to common shareholders was $149.3 million, or $3.13 diluted earnings per share, compared with $126.7 million in 2014. Growth in 2015 came mainly from DSA, where revenue rose $74.0 million, or 13.7%, driven by higher Safety Assessment study volume and the Argenta, BioFocus, ChanTest and Oncotest acquisitions. Manufacturing revenue rose $25.8 million, or 10.2%, on the Celsis and Sunrise acquisitions, while RMS revenue fell $34.2 million, or 6.7%, largely due to foreign exchange. Foreign currency reduced total 2015 revenue by $69.4 million, or 5.3%. Total debt and capital lease obligations were $863.0 million at year-end, and cash and cash equivalents were $117.9 million. Looking ahead, the company agreed on January 6, 2016 to acquire WIL Research for approximately $585.0 million in cash, expected to close early in the second quarter of 2016. The acquisition is to be financed through an expansion of the credit facility of up to $350.0 million and cash on hand. The filing also discloses an IDEXX patent infringement complaint, which the company intends to defend vigorously, and an internal investigation into inaccurate government contract billing, for which a liability of approximately $1.5 million has been recorded.
- 2014Feb 17, 2015
Charles River Laboratories International Annual Report, Year Ended Dec 27, 2014
Charles River Laboratories International, Inc. (CRL) reported fiscal 2014 total revenue of $1.30 billion (fiscal 2013: $1.17 billion) and operating income of $177.7 million, up from $151.4 million. Net income attributable to common shareholders was $126.7 million, and diluted earnings per share from continuing operations were $2.70, compared with $2.15 in 2013. Revenue growth was led by the Discovery and Safety Assessment (DSA) segment, which rose $105.8 million to $538.2 million, including $71.4 million contributed by the Argenta and BioFocus acquisition. Manufacturing Support grew $30.3 million to $252.1 million, while Research Models and Services (RMS) declined $3.9 million to $507.4 million. The company completed three acquisitions in 2014: Argenta and BioFocus in April (preliminary purchase price $183.1 million net of cash acquired), VivoPath in June, and ChanTest in October ($52.1 million net of cash acquired). Net cash provided by operating activities was $252.1 million, and capital expenditures were $56.9 million. Total debt was $753.8 million at year end, and the company repurchased about 2,093,000 shares for $110.6 million during 2014, leaving $178.5 million remaining under its repurchase authorization. The company paid no cash dividends and does not intend to pay them in the foreseeable future. The filing also discloses an investigation into inaccurate billing on certain government contracts in the RMS segment, for which the company has reserved approximately $1.5 million. Management reports that the company cannot yet estimate the potential range of loss beyond that reserve. Management also notes that the National Cancer Institute canceled a contract that had been worth $10 to $11 million annually.
- 2013Feb 25, 2014
Charles River Laboratories International Annual Report, Year Ended Dec 28, 2013
Charles River Laboratories International, Inc. reported net sales of $1,165.5 million for fiscal 2013, up 3.2% from $1,129.5 million in 2012, with operating income of $151.4 million (13.0% of net sales) versus $165.8 million in 2012. Net income attributable to common shareholders was $102.8 million, or $2.12 diluted EPS, compared with $97.3 million and $2.01 in 2012. Growth came from the Preclinical Services (PCS) segment, where sales rose 5.5% to $458.4 million and operating income increased to $44.1 million, while the Research Models and Services (RMS) segment grew 1.7% to $707.1 million but its operating income fell to $181.3 million from $202.4 million, affected by $13.5 million of accelerated depreciation tied to a California facility consolidation. Cash flow from operations was $209.0 million, and cash and cash equivalents rose to $155.9 million at year-end. Total debt was $663.0 million after a May 2013 refinancing into a $970 million credit facility maturing in May 2018. The company repurchased 3.5 million shares during 2013, and the Board approved $250 million in increases to its share buy-back program, leaving $139.1 million of remaining authorization. The company has not paid cash dividends in the past two years and does not intend to pay them in the foreseeable future. The filing also discloses an internal investigation, begun in May 2013, into inaccurate billing on certain government contracts within the RMS business. The company has reserved $1.5 million for excess amounts billed and states it cannot estimate a loss range beyond that reserve. Management reported that a material weakness in internal control over financial reporting identified as of December 29, 2012 had been remediated, and that internal controls were effective as of December 28, 2013.
- 2012Feb 27, 2013
Charles River Laboratories International Annual Report, Year Ended Dec 29, 2012
Charles River Laboratories International, Inc. reported net sales of $1,129.5 million for fiscal 2012, a decrease of 1.1% from $1,142.6 million in 2011, with the decline attributed primarily to unfavorable foreign currency translation of 2.0%. Operating income was $165.8 million (14.7% of net sales) versus $174.3 million in 2011, and net income attributable to common shareowners was $97.3 million, or $2.01 per diluted share, compared with $109.6 million, or $2.14 per diluted share, in 2011. The company operates two segments: Research Models and Services (RMS), which accounted for 61.5% of 2012 net sales with an operating margin of 29.1%, and Preclinical Services (PCS), which accounted for 38.5% of net sales with an operating margin of 8.0%. PCS backlog was $213.9 million at December 29, 2012. The filing discloses a material weakness in internal control over financial reporting as of December 29, 2012, related to segregation of duties, restricted access, changes to vendor and customer master data, transaction-level controls and financial close controls. Management concluded that disclosure controls were not effective, and PricewaterhouseCoopers LLP issued an adverse opinion on internal control while still opining that the financial statements were fairly presented. Management states remediation efforts began in the first quarter of 2013. Balance sheet and liquidity: total debt was $666.5 million, cash and cash equivalents were $109.7 million, and net cash from operating activities was $208.0 million. The company repurchased 1.7 million shares for $61.4 million in 2012 and has $54.8 million remaining under its $750 million repurchase program. The $350.0 million 2.25% Convertible Senior Notes mature in June 2013, and management intends to settle the principal in cash. The company acquired Accugenix for $16.9 million net of cash acquired and agreed to acquire a 75% interest in Vital River for approximately $26.8 million, which closed in the first quarter of 2013.
- 2011Feb 27, 2012
Charles River Laboratories International Annual Report, Year Ended Dec 31, 2011
Charles River Laboratories International, Inc. (CRL) reported 2011 net sales from continuing operations of $1,142.6 million, up 0.8% from $1,133.4 million in 2010, with growth driven mainly by the Research Models and Services (RMS) segment, partially offset by lower Preclinical Services (PCS) sales. Operating income was $174.3 million in 2011 versus an operating loss of $298.5 million in 2010, which included a $305.0 million goodwill impairment, $91.4 million in asset impairments and a $30.0 million termination fee. Net income attributable to common shareowners was $109.6 million, or $2.14 per diluted share, compared with a net loss of $336.7 million in 2010. Gross margin rose to 35.2% of net sales from 33.9%, reflecting cost-savings actions and higher RMS sales. The company describes its business as a provider of solutions that accelerate early-stage drug discovery and development, organized into two segments: RMS (61.7% of 2011 net sales) and PCS (38.3%). Management continued four key initiatives: improving operating margin, improving free cash flow, disciplined investment in growth businesses, and returning value to shareholders. During 2011 the company repurchased 8.4 million shares for approximately $300 million, and weighted average shares outstanding fell to 51.3 million from 62.6 million. Cash and cash equivalents declined to $68.9 million from $179.2 million, and total debt was $739 million at December 31, 2011. The filing also notes that PCS backlog was $202.5 million at December 31, 2011, compared with $219.9 million a year earlier, and that management describes market conditions as stabilizing but still uncertain. Risk disclosures highlight dependence on pharmaceutical and biotechnology R&D budgets, government NIH funding, health care reform, contract termination provisions and international operations, which represent roughly one-half of total net sales.
- 2010Feb 23, 2011
Charles River Laboratories International Annual Report, Year Ended Dec 25, 2010
Charles River Laboratories International, Inc. reported fiscal 2010 net sales of $1,133.4 million, down 3.3% from $1,171.6 million in 2009, and a net loss attributable to common shareowners of $336.7 million, compared with net income of $114.4 million in 2009. The loss was driven primarily by a $305.0 million goodwill impairment in the Preclinical Services (PCS) segment, $91.4 million of asset impairments (including $64.6 million for PCS-Massachusetts and $17.2 million for PCS-China), and a $30.0 million termination fee paid to WuXi PharmaTech in connection with the terminated acquisition. Operating loss was $298.5 million compared with operating income of $169.6 million a year earlier. Net sales in the Research Models and Services (RMS) segment rose 1.1% to $667.0 million, while PCS sales fell 8.8% to $466.4 million, and PCS operating results swung to a loss of $379.7 million. Management described a challenging market in which large pharmaceutical customers cut R&D spending, consolidated, and delayed decisions, creating excess preclinical capacity and pricing pressure. The company launched four initiatives in December 2010: improving operating margin, improving free cash flow, disciplined investment in growth businesses (GEMS, Discovery Services, In Vitro and Biopharmaceutical Services), and returning value to shareholders. It authorized a $500.0 million stock repurchase program, raised to $750.0 million, and executed a $300.0 million accelerated stock repurchase that settled on February 11, 2011, with $397.1 million remaining on the authorization. The company also announced it is pursuing strategic alternatives for its U.S. Phase I clinic in Tacoma, Washington, which is now presented as discontinued operations, and for its China preclinical facility. Liquidity became more constrained: total debt and capital lease obligations rose to $700.9 million at year-end from $492.8 million, and shareowners' equity fell to $687.4 million from $1,375.2 million. Cash and cash equivalents were $179.2 million, and net cash from operating activities was $168.2 million, down from $215.6 million. The company stated it expects 2011 capital expenditures of approximately $50.0 million.
- 2009Feb 19, 2010
Charles River Laboratories International Annual Report, Year Ended Dec 26, 2009
Charles River Laboratories International, Inc. reported net sales of $1.20 billion for fiscal 2009 (ended December 26, 2009), down $140.9 million, or 10.5%, from $1.34 billion in 2008. The decline was driven mainly by slower demand for Preclinical Services (PCS), where segment sales fell 20.6% to $542.6 million amid study slippage, delayed customer decisions, pricing pressure and unfavorable foreign currency. Research Models and Services (RMS) sales were flat at $659.9 million. Operating income rebounded to $166.9 million from a loss of $449.9 million in 2008, which included a $700 million goodwill impairment in the PCS segment. Net income attributable to common shareowners was $114.4 million, or $1.74 per diluted share, versus a loss of $524.5 million in 2008. Management described 2009 as a challenging year for preclinical services and said it expects PCS demand to begin ramping up slowly in the second quarter of 2010. To lower costs and align capacity, the company cut about 1,000 jobs, closed its Arkansas facility, and announced in January 2010 the suspension of its Shrewsbury, Massachusetts PCS facility by mid-2010, with expected charges of approximately $6 million to $7 million and cost savings of about $40 million in 2009 and $70 million in 2010. Cash flow from operations was $217.4 million, capital expenditures were $80.0 million, and total debt was $492.8 million at year-end. The company did not repurchase shares in the fourth quarter, with about $144.8 million remaining under its repurchase authorization. The filing identifies key risks including reduced pharmaceutical and biotechnology R&D budgets, customer termination rights on short notice, fixed-price contract exposure, international operations (roughly half of net sales), proposed U.S. and Canadian tax law changes, and goodwill impairment risk given $668.5 million of goodwill and other intangibles.
- 2008Feb 23, 2009
Charles River Laboratories International Annual Report, Year Ended Dec 27, 2008
Charles River Laboratories International, Inc. reported a net loss of $521.8 million for fiscal 2008 (fiscal year ended December 27, 2008), compared with net income of $154.4 million in 2007. The result was driven by a $700.0 million goodwill impairment charge related to the Preclinical Services (PCS) business, which produced an operating loss of $449.8 million for the company. Excluding that charge, the filing shows net sales growth: total net sales were $1,343.5 million, up 9.2% from $1,230.6 million in 2007. Research Models and Services (RMS) net sales rose 14.3% to $659.9 million, while PCS net sales rose 4.6% to $683.6 million, though demand decelerated in the second half of 2008 as pharmaceutical and biotechnology customers restructured and reprioritized pipelines. Management's outlook for 2009 is cautious. The company expects softer demand, particularly for preclinical services, at least until mid-year. It has taken cost actions including a hiring freeze, salary freeze, and a 3% headcount reduction, with a one-time charge of approximately $9.0 million, and is pursuing strategic alternatives for its Scotland Phase I clinical operation. Capital expenditures were $197.1 million in 2008 and are planned at $100 million to $120 million for 2009, and the Ohio expansion has been delayed until 2010. Total debt was $575.8 million at year-end, and shareholders' equity fell to $1,199.0 million from $1,860.5 million. For investors, the key points are the impairment's effect on reported earnings, the slowdown in preclinical demand, and the company's balance sheet and cash position. Cash and cash equivalents were $243.6 million, and operating cash flow was $279.5 million. The company repurchased $115.1 million of treasury stock during 2008 and expects to repatriate approximately $90.0 million of non-U.S. earnings in the first quarter of 2009.
- 2007Feb 20, 2008
Charles River Laboratories International Annual Report, Year Ended Dec 29, 2007
Charles River Laboratories International, Inc. reported net sales of $1,230.6 million for fiscal 2007 (ended December 29, 2007), up 16.3% from $1,058.4 million in 2006, driven by increased customer demand, higher pricing and the full-year impact of the Northwest Kinetics acquisition. Operating income rose to $227.2 million from $188.2 million, with the operating margin improving to 18.5% from 17.8%. Net income was $154.4 million, or $2.25 diluted earnings per share, compared with a net loss of $55.8 million in 2006, which had included a $181.0 million loss from discontinued operations. Income from continuing operations was $157.6 million, or $2.29 diluted per share, versus $125.2 million, or $1.79, in 2006. The Research Models and Services (RMS) segment, 46.9% of net sales, grew 12.1% to $577.2 million with an operating margin of 30.7%. The Preclinical Services (PCS) segment, 53.1% of net sales, grew 20.2% to $653.4 million with an operating margin of 15.8%. PCS backlog was approximately $393 million at year-end. The company is in a substantial capacity expansion program, with $227.0 million of capital expenditures in 2007 and a planned $220 million to $240 million in 2008, including a new Nevada PCS facility, a China facility due to open in late 2008, and a Maryland RMS facility supporting a 10-year National Cancer Institute agreement. Balance sheet items include total debt of $510.0 million (including $350.0 million of 2.25% convertible senior notes due 2013), cash and cash equivalents of $225.4 million, and goodwill and other intangibles of $1.3 billion. The company holds $38.2 million of auction rate securities, of which $14.2 million failed at auction in the first quarter of 2008. The company has not paid cash dividends in the past two years and does not intend to pay them in the foreseeable future, and it repurchased 199,200 shares in the fourth quarter under a $400.0 million authorization.
- 2006Feb 27, 2007
Charles River Laboratories International Annual Report, Year Ended Dec 30, 2006
Charles River Laboratories International, Inc. reported net sales from continuing operations of $1,058.4 million for fiscal 2006, up 6.5% from $993.3 million in 2005, and operating income of $188.2 million, versus $184.7 million a year earlier. The company reports two segments: Research Models and Services (RMS), with net sales of $515.0 million (48.7% of total), and Preclinical Services (PCS), which includes Phase I clinical services, with net sales of $543.4 million (51.3% of total, up 10.9%). Operating margin declined to 17.8% from 18.6%, mainly due to $11.7 million of stock option expense under SFAS 123(R). Net income was a loss of $(55.8) million in 2006, compared with net income of $142.0 million in 2005. The result was driven by a $181.0 million loss from discontinued operations, which included a $129.2 million goodwill impairment tied to the sale of the Phase II-IV Clinical Services business for approximately $215 million in cash and the decision to close the Interventional and Surgical Services business. Income from continuing operations fell to $125.2 million, or $1.79 diluted per share, from $145.8 million, or $2.02, in 2005. Balance sheet and cash flow activity was dominated by expansion and capital returns. Capital expenditures were $181.7 million in 2006, and the company projects $200 million to $225 million for 2007, with new preclinical facilities in Massachusetts and Nevada. Total debt rose to $572.1 million at December 30, 2006, from $296.1 million, after the issuance of $350.0 million of 2.25% convertible senior notes due 2013. The company also repurchased $250.0 million of treasury stock during 2006 and had $35.3 million remaining under its repurchase authorization at year-end.
- 2005Mar 14, 2006
Charles River Laboratories International Annual Report, Year Ended Dec 31, 2005
Charles River Laboratories International, Inc. reported net sales of $1,122.2 million for fiscal 2005, up 46.3% from $766.9 million in 2004, driven primarily by the October 2004 acquisition of Inveresk Research Group, with pro forma sales growth of 10.2%. Operating income was $181.0 million (16.1% of net sales) versus $160.3 million (20.9%) in 2004, reflected $58.2 million of amortization of other intangibles, and net income rose to $142.0 million, or $1.96 diluted EPS, from $89.8 million ($1.68) a year earlier. Net income was helped by a $28.3 million net tax benefit tied to the American Jobs Creation Act repatriation and a change in assertion on Inveresk pre-acquisition earnings, and the effective tax rate fell to 10.3% from 40.1%. By segment, Research Models and Services contributed 44.8% of 2005 net sales, Preclinical Services 43.5% (up 83.6%), and Clinical Services 11.6%. Management highlighted a 2006 capital expenditure plan of approximately $175 to $200 million for facility expansion, including a Massachusetts preclinical facility, a Nevada facility in 2007, and a California research models build-out. Backlog for Preclinical and Clinical Services was $448.2 million at December 31, 2005. Total debt fell to $296.7 million from $686.8 million after the conversion of $185 million of 3.5% convertible debentures into common stock and $337.5 million of debt repayments during 2005. The company has not paid cash dividends in the past two years and does not intend to in the foreseeable future. Under a share repurchase program, the Board authorized a total of $100.0 million, of which about $82.5 million remained available at year-end. Risks highlighted in the filing include dependence on outsourcing trends and R&D budgets, customer contracts terminable on little notice, goodwill of $1.4 billion from the Inveresk acquisition, and foreign currency exposure, particularly to the pound sterling and Canadian dollar.
- 2004-AMar 14, 2005
Charles River Laboratories International Annual Report (Amendment), Year Ended Dec 25, 2004
Charles River Laboratories International, Inc. filed this Amendment No. 1 to its Form 10-K for the fiscal year ended December 25, 2004. According to the explanatory note, the sole purpose of the amendment is to add the date, March 9, 2005, to the Report of Independent Registered Public Accounting Firm in Item 8. The original Form 10-K was filed with the SEC on March 9, 2005. The registrant is a Delaware corporation headquartered in Wilmington, Massachusetts, with common stock listed on the New York Stock Exchange. The filing reports an aggregate market value of voting common stock held by non-affiliates of approximately $2,150,196,678 as of June 25, 2004, and 66,109,790 shares outstanding as of March 1, 2005. The auditor, PricewaterhouseCoopers LLP, issued an integrated audit opinion covering the 2004 consolidated financial statements, the financial statement schedule, and the effectiveness of internal control over financial reporting as of December 25, 2004. The auditor also covered the December 27, 2003 and December 28, 2002 consolidated financial statements. The firm concluded that the company maintained effective internal control over financial reporting in all material respects, based on the COSO Internal Control framework. Management excluded Inveresk Research Group, Inc., which the company acquired in a purchase business combination during 2004, from its internal control assessment, and the auditor likewise excluded it from its audit. The filing states that Inveresk's total assets and total revenues represent 67% and 7.9%, respectively, of the related consolidated amounts for the year ended December 25, 2004. Part III information is incorporated by reference from the 2005 Proxy Statement for the annual meeting scheduled for May 9, 2005.
- 2004Mar 9, 2005
Charles River Laboratories International Annual Report, Year Ended Dec 25, 2004
Charles River Laboratories International, Inc. reported fiscal 2004 net sales of $766.9 million, up 25.0% from $613.7 million in 2003, and operating income of $160.3 million, compared with $138.6 million in 2003. Net income was $89.8 million, or $1.68 per diluted share, versus $80.2 million, or $1.64 per diluted share, in 2003. Results include only the nine weeks of 2004 during which Inveresk Research Group, which was acquired in October 2004, was owned by the company. The filing states that Inveresk contributed 9.9% of the net sales gain and that operating margin was reduced by 2.2% from Inveresk-related amortization, stock-based compensation, and a $3.0 million Proteomics write-off. The company reorganized into three segments. Research Models and Services generated $476.7 million, or 62.2% of 2004 net sales, with operating income of 32.0% of segment sales. Preclinical Services generated $266.0 million, or 34.7% of net sales, and grew 43.3%. Clinical Services, newly created through Inveresk, contributed $24.3 million, or 3.2% of net sales. Backlog for Preclinical and Clinical Services was approximately $425.0 million at December 25, 2004. The Inveresk acquisition substantially changed the balance sheet. Goodwill rose to $1.42 billion from $105.3 million, and total assets reached $2.63 billion from $799.6 million. Total debt was $685.8 million at year-end, compared with $186.0 million a year earlier, after a $400 million term loan and a $150 million revolving facility were put in place in October 2004. The filing cites risks from this debt level, from goodwill impairment, and from exchange-rate exposure, particularly to the pound sterling and Canadian dollar.
- 2003-AApr 12, 2004
Charles River Laboratories International Annual Report (Amendment), Year Ended Dec 27, 2003
This filing is Amendment No. 1 to the Form 10-K of Charles River Laboratories International, Inc. for the fiscal year ended December 27, 2003, signed April 8, 2004 and filed on April 12, 2004. The company is a Delaware corporation headquartered in Wilmington, Massachusetts, with common stock listed on the New York Stock Exchange. The amendment does not change the original report; its sole stated purpose is to remove the check mark from the cover-sheet box relating to Item 405 of Regulation S-K. The original Form 10-K was filed with the SEC on March 10, 2004. According to the filing, the aggregate market value of common stock held by non-affiliates was approximately $1,453,176,300 as of June 28, 2003, and 46,074,943 shares were outstanding as of March 3, 2004. Portions of the Definitive Proxy Statement for the 2004 Annual Meeting of Stockholders, scheduled for May 12, 2004, are incorporated by reference into Part III. This amendment contains no financial statements, operating results, or business discussion. It is signed by James C. Foster, President, Chief Executive Officer and Chairman, and Thomas F. Ackerman, Senior Vice President and Chief Financial Officer, along with the board of directors, and it includes certifications under Rules 13a-14(a) and 15d-14(a) and Section 1350 as exhibits.
- 2003Mar 10, 2004
Charles River Laboratories International Annual Report, Year Ended Dec 27, 2003
Charles River Laboratories International, Inc. reported net sales of $613.7 million for fiscal 2003 (ended December 27, 2003), up 10.7% from $554.6 million in 2002, and operating income of $138.6 million, up 13.3%. Net income was $80.2 million, or $1.64 per diluted share, compared with $50.1 million, or $1.06 per diluted share, in 2002. The filing attributes growth mainly to the Research Models and Services (RMS) segment, which generated 66.0% of net sales and grew 14.5%, with operating margin rising to 31.2% from 29.0%. The Development and Safety Testing (DST) segment represented 34.0% of net sales and grew 3.9%, but its operating margin fell to 13.3% from 17.0%, partly due to the closure of a contract manufacturing facility and weak early-2003 toxicology demand. The company ended 2003 with cash and cash equivalents of $182.3 million, up from $122.5 million, and net cash provided by operating activities of $123.8 million. Total debt was $186.0 million, consisting mainly of $185.0 million of 3.5% senior convertible debentures due 2022. Shareholders' equity rose to $464.6 million. Management stated that no material legal proceedings were pending, and that the company's revolving credit facility of $100.0 million was undrawn at year end. The filing also flags risks, including dependence on pharmaceutical and government research funding, contract terminability on short notice, international currency exposure (international revenues were 30.8% of net sales), and a possible IRS challenge to tax benefits from the 1999 recapitalization, which carried a deferred tax asset of $71.6 million at year end. Subsequent events include the January 2004 acquisition of River Valley Farms for approximately $17.3 million and a first-quarter 2004 European reorganization expected to produce a one-time non-cash charge of approximately $7.9 million.
- 2002Mar 20, 2003
Charles River Laboratories International Annual Report, Year Ended Dec 28, 2002
Charles River Laboratories International, Inc. reported net sales of $554.6 million for fiscal 2002, up 19.1% from $465.6 million in 2001, with operating income of $122.3 million, a 35.4% increase over 2001. Net income was $50.1 million, compared with $35.4 million in 2001. Income before extraordinary item was $68.4 million, or $1.42 per diluted share, and the extraordinary loss was $18.2 million, net of tax, mainly from debt repayments. The company operates in two segments: Research Models, which contributed 40.3% of 2002 net sales and was the most profitable at a 31.7% operating margin, and Biomedical Products and Services, which contributed 59.7% of net sales. Cash from operations rose to $133.7 million in 2002 from $71.3 million in 2001. The company refinanced its debt during the year by issuing $185.0 million of 3.5% senior convertible debentures due 2022 and using the proceeds to retire the 13.5% senior subordinated notes. It also repaid its senior secured term loans and terminated its revolving credit facility, and it is negotiating a $100-125 million line of credit expected to close in March 2003. Total debt was $195.8 million at year end, and shareholders' equity was $357.4 million. The filing highlights risks including exposure to government and pharmaceutical research spending, customer contracts that can be terminated on little or no notice, and foreign currency exposure, since the company does not hedge. It also notes a $78.5 million deferred tax asset tied to a 1999 recapitalization election that the IRS could challenge. In 2002, development services faced weaker performance in two smaller units, and management expects development services performance to improve by the end of 2003.
- 2001Mar 27, 2002
Charles River Laboratories International Annual Report, Year Ended Dec 29, 2001
Charles River Laboratories International, Inc. reported net sales of $465.6 million for the fiscal year ended December 29, 2001, up $159.0 million, or 51.9%, from $306.6 million in 2000. The increase was driven largely by the first-quarter 2001 acquisitions of Pathology Associates International Corporation (PAI) and Primedica Corporation, which contributed $118.0 million of sales. On a pro forma basis, sales increased 15.0%. Biomedical products and services grew to 58% of 2001 net sales, while research models, the company's historical core business, accounted for 42%. Operating income rose to $90.3 million from $65.1 million, and net income was $35.4 million, compared with a net loss of $11.2 million in 2000. Results include a $5.2 million after-tax extraordinary loss on debt repayment. Cash flow and the balance sheet improved meaningfully. Net cash provided by operating activities was $71.3 million, cash and cash equivalents were $58.3 million at year-end, and total debt was $156.8 million, down from $202.9 million. Shareholders' equity rose to $289.5 million. The company completed two 2001 follow-on stock offerings with combined net proceeds of $116.7 million, which were used largely to repay debt and fund acquisitions. Subsequent to year-end, the company issued $185.0 million par value of 3.5% senior convertible debentures due 2022 (including the additional $10.0 million option exercised February 11, 2002), with a conversion price of $38.87, and used part of the proceeds to tender for $79.7 million par value of its 13.5% senior subordinated notes at a premium of approximately 29.5%. The filing also flags risks including contamination in animal populations, changes to the Animal Welfare Act, competition, dependence on pharmaceutical and biotechnology customer spending, and the possibility that the Internal Revenue Service could challenge the tax benefits tied to the 1999 recapitalization.
- 2000Mar 30, 2001
Charles River Laboratories International Annual Report, Year Ended Dec 31, 2000
Charles River Laboratories International, Inc. reported net sales of $306.6 million for the fiscal year ended December 30, 2000, up $75.2 million, or 32.5%, from $231.4 million in 1999. Operating income rose to $65.1 million from $43.0 million. The company's research models segment, its historical core business, accounted for 61.2% of 2000 net sales, while biomedical products and services accounted for 38.8%. The biomedical segment grew faster, with net sales of $118.9 million, up 50.7%, and the filing cites a 33.7% compound annual growth rate in net sales over the past five fiscal years. Acquisitions, including Sierra and the consolidation of Charles River Japan, contributed to the growth. The company posted a net loss of $11.2 million in 2000, compared with net income of $17.1 million in 1999. The loss reflects a $29.1 million extraordinary loss, net of tax, from early debt repayment after the June 2000 initial public offering of 16,100,000 shares at $16.00 per share. Interest expense rose to $40.7 million from $12.8 million, reflecting debt taken on in the 1999 recapitalization. Total debt fell to $202.9 million from $386.0 million at the end of 1999, and shareholders' equity was $116.9 million, compared with a deficit of $110.1 million a year earlier. Cash from operations was $33.8 million, and capital expenditures were $15.6 million. After year-end, the company acquired Pathology Associates International for $37 million and Primedica for approximately $52 million. In March 2001 it completed a public offering of 3,500,000 shares at $19.00 per share, with net proceeds of approximately $62.5 million, which it intends to use to repay debt and retire acquisition obligations. Key risks noted in the filing include the possibility that the IRS challenges a $92.3 million net deferred tax asset tied to a Section 338(h)(10) election, contamination in animal populations, industry consolidation among pharmaceutical customers, and the influence of DLJ Merchant Banking Partners, which beneficially owns approximately 30.0% of common stock.
- 1999May 8, 2000
Charles River Laboratories International Annual Report, Year Ended Dec 25, 1999
Charles River Laboratories Holdings, Inc. reported fiscal 1999 total net sales of $219.3 million ($219,276 thousand), up from $193.3 million in 1998 and $170.7 million in 1997. Growth came from both segments: net sales related to services rose to $39.0 million from $23.9 million, and net sales related to products rose to $180.3 million from $169.4 million. Operating income increased to $43.0 million from $35.3 million, but net income fell to $17.1 million from $23.4 million, or $1.66 per share versus $2.27. The decline reflected interest expense of $12.8 million, compared with $0.4 million in 1998, following the recapitalization. On September 29, 1999, CRL Acquisition LLC, an affiliate of DLJ Merchant Banking Partners II, L.P. and affiliated funds, acquired 87.5% of the common stock of Charles River Laboratories, Inc. from Bausch & Lomb for approximately $443 million, in a leveraged recapitalization accounted for without changing the historical basis of assets and liabilities. Bausch & Lomb subsidiaries retained 12.5%. The transaction left the company with total liabilities of $459.7 million, long-term debt of $381.7 million, and a shareholders' deficit of $(110.1) million at year-end. The filing states the holding company has no source of liquidity of its own, so repayment depends on dividends from the operating subsidiary, which are restricted by debt terms, or on a refinancing or equity transaction. Operating cash flow was $37.6 million in 1999, roughly flat with $37.4 million in 1998, and capital expenditures were $13.0 million. The company spent $23.1 million on acquisitions, including Sierra, a preclinical biomedical services company acquired for about $23.3 million. Subsequent events include the acquisition of an additional 16% of the Charles River Japan joint venture for 1.4 billion yen ($12,844 thousand), which will bring its operations into consolidation, and the planned closure of the Shamrock primate import business in England.